Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma

Publication date: Available online 25 September 2019Source: Seminars in Cancer BiologyAuthor(s): Faheem Hyder Pottoo, Md. Abul Barkat, Harshita, Mohammad Azam Ansari, Md. Noushad Javed, Qazi Mohammad Sajid Jamal, Mohammad Amjad KamalAbstractNeuroblastoma (NB) is a widely diagnosed cancer in children, characterized by amplification of the gene encoding the MYCN transcription factor, which is highly predictive of poor clinical outcome and metastatic disease. microRNAs (a class of small non-coding RNAs) are regulated by MYCN transcription factor in neuroblastoma cells. The current research is focussed on identifying differential role of miRNAs and their interactions with signalling proteins, which are intricately linked with cellular processes like apoptosis, proliferation or metastasis. However, the therapeutic success of miRNAs is limited by pharmaco-technical issues which are well counteracted by nanotechnological advancements. The nanoformulated miRNAs unload anti-cancer drugs in a controlled and prespecified manner at target sites, to influence the activity of target protein in amelioration of NB. Recent advances and developments in the field of miRNAs-based systems for clinical management of NBs and the role of nanotechnology to overcome challenges with drug delivery of miRNAs have been reviewed in this paper.Graphical abstract
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research

Related Links:

Conditions:   Refractory Cancer;   Refractory Neoplasm;   Cancer Pediatric;   Refractory Tumor;   Pediatric Cancer;   Pediatric Brain Tumor;   Neuroblastoma;   Neuroblastoma Recurrent;   Pediatric Lymphoma;   Pediatric Meningioma Interventions:   Drug: 9-ING-41;   Drug: Irinotecan Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 22 January 2020Source: Journal of Advanced ResearchAuthor(s): Noela Rodríguez-Losada, Javier de la Rosa, María Larriva, Rune Wendelbo, José A. Aguirre, Javier S. Castresana, Santiago J. BallazAbstractAlpha-Synuclein (aSyn) is a chameleon-like protein. Its overexpression and intracellular deposition defines neurodegenerative α-synucleinopathies including Parkinsońs disease. Whether aSyn up-regulation is the cause or the protective reaction to α-synucleinopathies remains unresolved. Remarkably, the accumulation of aSyn is involved in cancer. Here, the neuro...
Source: Journal of Advanced Research - Category: Research Source Type: research
CONCLUSIONS: Since only one eligible RCT evaluating the use of a continuous cisplatin infusion versus a one-hour bolus cisplatin infusion was found, and that had methodological limitations, no definitive conclusions can be made. It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. For other (combinations of) infusion durations and other platinum analogues no eligible studies were identified. More high-quality research is needed. PMID: 31961948 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
SummaryAnaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system development. Due to chromosomal translocations, point mutations, and gene amplification, constitutively activated ALK has been implicated in a variety of human cancers, including anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer, and neuroblastoma. We evaluated the anti-cancer activity of the ALK inhibitor KRCA-0008 using ALCL cell lines that express NPM (nucleophosmin)-ALK. KRCA-0008 strongly suppressed the proliferation and survival of NPM-ALK-positive ALCL ...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
olo A Abstract Patients with high-risk neuroblastoma (HR-NB) often initially respond to therapy, but afterward they become resistant and disease recurred. Unfortunately, it does not exist one or more specific chromosome defects associated with relapse or refractory NB. Recently, genomic evidence from primary tumors indicated that the distal region of chromosome 6q is loss in HR-NB patients with fatal outcome. We identified a minimal common region of loss of chromosome 6q27 spanning an area of 2.09 Mb by high-resolution DNA copy number data of a small cohort of HR-NB samples carrying 6q loss. This region of loss ha...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Publication date: 14 January 2020Source: Cell Reports, Volume 30, Issue 2Author(s): Jesus García-López, Kirby Wallace, Joel H. Otero, Rachelle Olsen, Yong-dong Wang, David Finkelstein, Brian L. Gudenas, Jerold E. Rehg, Paul Northcott, Andrew M. Davidoff, Kevin W. FreemanSummaryLoss of heterozygosity (LOH) at 1p36 occurs in multiple cancers, including neuroblastoma (NBL). MYCN amplification and 1p36 deletions tightly correlate with markers of tumor aggressiveness in NBL. Although distal 1p36 losses associate with single-copy MYCN tumors, larger deletions correlate with MYCN amplification, indicating two tumor ...
Source: Cell Reports - Category: Cytology Source Type: research
In this study, taking into account the antiapoptotic and antioxidant activities of estrogens in neuronal cells, which are mediated by estrogen receptors, the possible estrogenic activity of aluminum in SH-SY5Y neuroblastoma cells was studied. Our results showed that aluminum in the form of aluminum chlorohydrate (ACH) exhibited no effect on estrogen receptors transcriptional activation, and differential effect on estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) protein levels. ACH caused reduction in ERβ protein levels, and increase in its mitochondrial localization. ACH-induced reduction in E...
Source: Neurotoxicology - Category: Neurology Authors: Tags: Neurotoxicology Source Type: research
In this study, we found that WDR5 promoted the proliferation and self-renewal of glioblastoma and neuroblastoma cells. The data from databases and Western blot assay showed that CARM1 is a downstream gene of WDR5-Myc axis. In addition, we observed that WDR5 promoted the binding of Myc to CARM1 promoter by interacting with Myc and inducing histone 3 lysine 4 trimethylation (H3K4me3). Dual luciferase reporter system indicated that Myc binds to the upstream region (-520 to -515) before transcription start site (TSS) of CARM1 promoter. These findings suggest a novel regulatory model for the proliferation and tumorigenesis...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
AbstractNeuroblastoma (NB) is a pediatric tumor of embryonic origin. About 1 –2% of all NBs are familial cases, and genetic predisposition is suspected for the remaining cases. During the last decade, genome-wide association studies (GWAS) and high-throughput sequencing approaches have been used to identify associations among common and rare genetic variants and NB risk. S ubstantial data has been produced by large patient cohorts that implicate various genes in NB tumorigenesis, such asCASC15,BARD1,CHEK2,LMO1,LIN28B,AXIN2, BRCA1, TP53,SMARCA4, andCDK1NB. NB, as well as other pediatric cancers, has few recurrent muta...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 10 January 2020; doi:10.1038/s41416-019-0682-4Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Biology | Brain | Cancer | Cancer & Oncology | Child Development | Children | Genetics | Nanotechnology | Neuroblastoma | Neurology